 |
|
|
| |
Early and Week 52 biomarker (MRI-PDFF, ALT, MRE and PRO-C3) responses to resmetirom predict improvements in MASH and liver
fibrosis
|
| |
| |
ESL 2026 May 26-30 Barcelona
Rohit Loomba1, Rebecca Taub2, Krishna Padmanabhan2, Dominic Labriola2, Mazen Noureddin3, Naim Alkhouri3. 1San Diego
School of Medicine, San Diego, United States; 2Madrigal
Pharmaceuticals, Conshohocken, United States; 3Pinnacle, San Antonio, United States
|
| |
|
|
|
|
|
